"Our highly focused and custom next generation sequencing panel for CLL affords excellent depth of detection of variants in genes of high prognostic value in CLL patients," said Jane Houldsworth, Ph.D., Vice President of Research and Development at CGI. "For the first time, comprehensive, robust mutation analysis down to at least 5% sensitivity of genes such as TP53, NOTCH1, SF3B1, and uniquely ATM and BIRC3 are being offered in a clinically-regulated setting with results made available to clinicians in a streamlined and informative report to assist in the management of CLL patients."
globenewswire.com/news-rele...
Quite a few of us would have had a basic FISH panel test to check for common bad genomic prognostic indicators for CLL and a select few of us - perhaps as part of trial, have been tested for a much wider range of indicators. In the above article, CGI are trying to tell the CLL world that their Focus::CLL (TM) panel has been selected for a trial that is expected to assess several hundred patient specimens during 2015. Will this panel eventually gain acceptance for common usage? I guess we'll have to wait and see...
If ATM, BIRC3, NOTCH1, SF3B1 and TP53 don't mean a thing to you, check out Dr Sharman's blog on prognostic markers in CLL:
cll-nhl.com/2012/12/new-cll...
Neil
Photo: This meal should keep the ants satisfied for a while!
Does CLL begin neonatal?
OSU Trial Update Cycle 9, Day 1
Methylation focus on CLL
